Mikkel E I Kolind, Rikke Kruse, Jan C Brønd, Afsaneh M Nejad, Lasse K Bak, Charlotte S Larsen, Kurt Højlund, Christoph P Beier, Elsebeth Stenager, Claus B Juhl
{"title":"Attenuated PER3 amplitude in hair follicles is associated with sleep irregularity in schizophrenia.","authors":"Mikkel E I Kolind, Rikke Kruse, Jan C Brønd, Afsaneh M Nejad, Lasse K Bak, Charlotte S Larsen, Kurt Højlund, Christoph P Beier, Elsebeth Stenager, Claus B Juhl","doi":"10.1038/s41398-026-04295-w","DOIUrl":null,"url":null,"abstract":"<p><p>Circadian dysregulation is prevalent in both schizophrenia and obesity, yet the molecular mechanisms underpinning these disturbances remain unclear. We examined circadian variation in clock gene expression using repeated hair follicle self-sampling across two days in 66 adults: 22 with schizophrenia and obesity (SCH-OB), 22 with obesity but no psychiatric disorder (OB), and 22 normal-weight controls (LEAN). Gene expression was quantified by qPCR, and complementary markers included salivary cortisol and melatonin, oral pH and temperature, and accelerometer-derived sleep metrics. Evidence of rhythmic expression was detected in five of six clock genes. PER3 amplitude was significantly reduced in SCH-OB compared with both OB and LEAN (p < 0.01) and correlated positively with sleep regularity (p = 0.006). Cortisol rhythms were preserved across groups, whereas melatonin amplitude was attenuated in SCH-OB relative to LEAN (p < 0.05). Hair follicle sampling proved highly feasible, with >98% compliance. These findings indicate that individuals with schizophrenia exhibit dampened circadian rhythms in PER3 expression that parallel irregular sleep patterns, supporting hair follicle-based sampling as a practical tool for assessing molecular rhythm parameters in real-world conditions.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710538/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-026-04295-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Circadian dysregulation is prevalent in both schizophrenia and obesity, yet the molecular mechanisms underpinning these disturbances remain unclear. We examined circadian variation in clock gene expression using repeated hair follicle self-sampling across two days in 66 adults: 22 with schizophrenia and obesity (SCH-OB), 22 with obesity but no psychiatric disorder (OB), and 22 normal-weight controls (LEAN). Gene expression was quantified by qPCR, and complementary markers included salivary cortisol and melatonin, oral pH and temperature, and accelerometer-derived sleep metrics. Evidence of rhythmic expression was detected in five of six clock genes. PER3 amplitude was significantly reduced in SCH-OB compared with both OB and LEAN (p < 0.01) and correlated positively with sleep regularity (p = 0.006). Cortisol rhythms were preserved across groups, whereas melatonin amplitude was attenuated in SCH-OB relative to LEAN (p < 0.05). Hair follicle sampling proved highly feasible, with >98% compliance. These findings indicate that individuals with schizophrenia exhibit dampened circadian rhythms in PER3 expression that parallel irregular sleep patterns, supporting hair follicle-based sampling as a practical tool for assessing molecular rhythm parameters in real-world conditions.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.